Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:31:27 ON 24 APR 2008

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:31:43 ON 24 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 23 APR 2008 HIGHEST RN 1016892-81-1
DICTIONARY FILE UPDATES: 23 APR 2008 HIGHEST RN 1016892-81-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\09998009_cddome_2.str



chain nodes :
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
44 45 46 47 48 49 50 51 52 53 54 55
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
chain bonds :

1-25 1-26 2-23 3-24 4-33 5-27 6-34 8-28 9-37 9-38 10-35 10-36 11-45
12-32 13-44 14-29 15-43 16-52 17-41 17-42 18-39 18-40 19-46 19-47 20-30
20-31 21-48 21-49 22-50 22-51 52-53 52-55 53-54
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13
13-14 13-15 14-18 15-16 15-19 16-17 16-22 17-18 19-20 20-21 21-22
exact/norm bonds :
1-2 1-6 2-3 2-23 3-4 4-5 5-6 5-7 6-10 7-8 7-11 8-9 8-14 9-10 11-12
12-13 12-32 13-14 13-15 14-18 15-16 15-19 16-17 16-22 17-18 19-20 20-21
21-22 52-53 52-55
exact bonds :
1-25 1-26 3-24 4-33 5-27 6-34 8-28 9-37 9-38 10-35 10-36 11-45 13-44
14-29 15-43 16-52 17-41 17-42 18-39 18-40 19-46 19-47 20-30 20-31 21-48
21-49 22-50 22-51 53-54

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS
28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS
36:CLASS 37:CLASS 38:CLASS 39:CLASS 40:CLASS 41:CLASS 42:CLASS 43:CLASS
44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS 51:CLASS
52:CLASS 53:CLASS 54:CLASS 55:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 exa
SAMPLE SEARCH INITIATED 16:32:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED        1 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            1 TO       80
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA EXA SAM L1

=> s l1 full
FULL SEARCH INITIATED 16:32:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      118 TO ITERATE

100.0% PROCESSED      118 ITERATIONS                                2 ANSWERS
SEARCH TIME: 00.00.01

L3            2 SEA SSS FUL L1

=> d l3

L3   ANSWER 1 OF 2  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   418764-26-8  REGISTRY
ED   Entered STN:  20 May 2002
CN   Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester, compd.
     with methanol (1:1), monohydrate (9CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C32 H43 N O4 . C H4 O . H2 O
SR   CA
LC   STN Files:   CA, CAPLUS, IMSRESEARCH

     CM   1

     CRN  218600-53-4
     CMF  C32 H43 N O4

Absolute stereochemistry.  Rotation (+).
```




```
     CM   2
```

CRN 67-56-1
CMF C H4 O

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	180.36	180.57

FILE 'MEDLINE' ENTERED AT 16:32:31 ON 24 APR 2008

FILE 'CAPLUS' ENTERED AT 16:32:31 ON 24 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE 'WPIDS' ENTERED AT 16:32:31 ON 24 APR 2008

FILE 'USPATFULL' ENTERED AT 16:32:31 ON 24 APR 2008

=> s l3
SAMPLE SEARCH INITIATED 16:32:43 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L4 34 L3

=> s l4 and (cancer? or ?tumor?)
L5 28 L4 AND (CANCER? OR ?TUMOR?)

=> s l5 not py>2002
L6 6 L5 NOT PY>2002

=> d l6 1-6 ibib, abs, hitstr

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:505732 CAPLUS
DOCUMENT NUMBER: 138:66283
TITLE: An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis
AUTHOR(S): Kim, Youngsoo; Suh, Nanjoo; Sporn, Michael; Reed, John C.

CORPORATE SOURCE: Burnham Institute, La Jolla, CA, 92037, USA
SOURCE: Journal of Biological Chemistry (2002), 277(25), 22320-22329
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB TRAIL (Apo2 ligand) is a member of the tumor necrosis factor (TNF) family of cytokines that induces apoptosis. Because TRAIL preferentially kills tumor cells, sparing normal tissues, interest has emerged in applying this biol. factor for cancer therapy in humans. However, not all tumors respond to TRAIL, raising questions about resistance mechanisms. We demonstrate here that a variety of natural and synthetic ligands of peroxisome proliferator-activated receptor-γ (PPARγ) sensitize tumor but not normal cells to apoptosis induction by TRAIL. PPARγ ligands selectively reduce levels of FLIP, an apoptosis-suppressing protein that blocks early events in TRAIL/TNF family death receptor signaling. Both PPARγ agonists and antagonists displayed these effects, regardless of the levels of PPARγ expression and even in the presence of a PPARγ dominant-neg. mutant, indicating a PPARγ-independent mechanism. Redns. in FLIP and sensitization to TRAIL-induced apoptosis were also not correlated with NF-κB, further suggesting a novel mechanism. PPARγ modulators induced ubiquitination and proteasome-dependent degradation of FLIP, without concomitant redns. in FLIP mRNA. The findings suggest the existence of a pharmacol. regulated novel target of this class of drugs that controls FLIP protein turnover, and raise the possibility of combining PPARγ modulators with TRAIL for more efficacious elimination of tumor cells through apoptosis.

IT 218600-53-4
RL: BUU (Biological use, unclassified); PAC (Pharmacological activity); BIOL (Biological study); USES (Uses)
(inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis)

RN 218600-53-4 CAPLUS
CN Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS

ACCESSION NUMBER: 2002:211223 CAPLUS
DOCUMENT NUMBER: 137:109396
TITLE: A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production
AUTHOR(S): Honda, Tadashi; Honda, Yukiko; Favaloro, Frank G.; Gribble, Gordon W.; Suh, Nanjoo; Place, Andrew E.; Rendi, Mara H.; Sporn, Michael B.
CORPORATE SOURCE: Department of Chemistry, Dartmouth College, Hanover, NH, 03755, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2002), 12(7), 1027-1030
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:109396

AB New oleanane triterpenoids with various substituents at the C-17 position of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and Me 2-carboxy-3,12-dioxooleana-1,9(11)-dien-28-oate were synthesized. Among them, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-onitrile shows extremely high inhibitory activity (IC50 = 1 pM level) against production of nitric oxide induced by interferon-γ in mouse macrophages. This potency is about 100 times and 30 times more potent than CDDO and dexamethasone, resp.

IT 218600-53-4P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of dicyanotriterpenoids and their inhibitory activity against production of nitric oxide induced by interferon-γ in mouse macrophages)

RN 218600-53-4 CAPLUS
CN Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:95270 CAPLUS
DOCUMENT NUMBER: 136:379616
TITLE: Identification of a novel synthetic triterpenoid, methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that

potently induces caspase-mediated apoptosis in human lung cancer cells

AUTHOR(S): Kim, Kevin B.; Lotan, Reuben; Yue, Ping; Sporn, Michael B.; Suh, Nanjoo; Gribble, Gordon W.; Honda, Tadashi; Wu, Gen Sheng; Hong, Waun Ki; Sun, Shi-Yong

CORPORATE SOURCE: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA

SOURCE: Molecular Cancer Therapeutics (2002), 1(3), 177-184
CODEN: MCTOCF; ISSN: 1535-7163

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Lung cancer continues to be the leading cause of cancer -related death in the United States. Therefore, new agents targeting prevention and treatment of lung cancer are urgently needed. In the present study, we demonstrate that a novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-dien-28-oate (CDDO-Me) is a potent inducer of apoptosis in human non-small cell lung carcinoma (NSCLC) cells. The concns. required for a 50% decrease in cell survival (IC50) ranged from 0.1 to 0.3 μM. CDDO-Me induced rapid apoptosis and triggered a series of effects associated with apoptosis including a rapid release of cytochrome c from mitochondria, activation of procaspase-9, -7, -6, and -3, and cleavage of poly(ADP-ribose) polymerase and lamin A/C. Moreover, the caspase-3 inhibitor Z-DEVD-FMK and the pan caspase inhibitor Z-VAD-FMK suppressed CDDO-Me-induced apoptosis. These results indicate that CDDO-Me induced apoptosis in human NSCLC cells via a cytochrome c-triggered caspase activation pathway. CDDO-Me did not alter the level of Bcl-2 and Bcl-xL proteins, and no correlation was found between cell sensitivity to CDDO-Me and basal Bcl-2 expression level. Furthermore, overexpression of Bcl-2 did not protect cells from CDDO-Me-induced apoptosis. These results suggest that CDDO-Me induces apoptosis in NSCLC cells irresp. of Bcl-2 expression level. In addition, no correlation was found between cell sensitivity to CDDO-Me and p53 status, suggesting that CDDO-Me induce a p53-independent apoptosis. Our results demonstrate that CDDO-Me may be a good candidate for addnl. evaluation as a potential therapeutic agent for human lung cancers and possibly other types of cancer.

IT 218600-53-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(identification of a novel synthetic triterpenoid, Me-2-cyano-3,12-dioxooleana-1,9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells)

RN 218600-53-4 CAPLUS

CN Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:29939 CAPLUS
DOCUMENT NUMBER: 136:318974
TITLE: Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia
AUTHOR(S): Konopleva, Marina; Tsao, Twee; Ruvolo, Peter; Stiouf, Irina; Estrov, Zeev; Leysath, Clinton E.; Zhao, Shourong; Harris, David; Chang, Shirong; Jackson, C. Ellen; Munsell, Mark; Suh, Nanjoo; Gribble, Gordon; Honda, Tadashi; May, W. Stratford; Sporn, Michael B.; Andreeff, Michael
CORPORATE SOURCE: Department of Blood and Marrow Transplantation, Section of Molecular Hematology and Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 77030, USA
SOURCE: Blood (2002), 99(1), 326-335
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: American Society of Hematology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oleic acid (CDDO) inhibits proliferation and induces differentiation and apoptosis in myeloid leukemia cells. This work studied the effects of the C-28 Me ester of CDDO, CDDO-Me, on cell growth and apoptosis of leukemic cell lines and primary acute myelogenous leukemia (AML). CDDO-Me decreased the viability of leukemic cell lines, including multidrug resistant (MDR)-1-overexpressing, p53null HL-60-Dox and primary AML cells, and it was 3-5-fold more active than CDDO. CDDO-Me induced a loss of mitochondrial membrane potential, induced caspase-3 cleavage, and increased annexin V binding and DNA fragmentation, suggesting the induction of apoptosis. CDDO-Me induced the proapoptotic Bax protein that precedes caspase activation. Furthermore, CDDO-Me inhibited the activation of ERK1/2, as determined by the inhibition of mitochondrial ERK1/2 phosphorylation, and it blocked Bcl-2 phosphorylation, rendering Bcl-2 less antiapoptotic. CDDO-Me induced granulo-monocytic differentiation in HL-60 cells and monocytic differentiation in primary cells. Colony formation of AML progenitors was inhibited in a concentration-dependent fashion, whereas normal CD34+ progenitor cells were less affected. Combinations with all-trans-retinoic acid or the retinoic acid receptor-specific ligand LG100268 enhanced the effects of CDDO-Me on the cell viability and

terminal differentiation of myeloid leukemic cell lines. In conclusion, CDDO-Me is an MDR-1- and a p53-independent compound that exerts strong antiproliferative, apoptotic, and differentiating effects in myeloid leukemic cell lines and in primary AML samples when used in submicromolar concns. The differential effects of CDDO-Me on leukemic and normal progenitor cells suggest that CDDO-Me has potential as a novel compound in the treatment of hematol. malignancies.

IT 218600-53-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(triterpenoid CDDO-Me induction of apoptosis and differentiation in acute myelogenous leukemia)

RN 218600-53-4 CAPLUS

CN Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:632697 CAPLUS

DOCUMENT NUMBER: 133:350364

TITLE: Synthetic Oleanane and Ursane Triterpenoids with Modified Rings A and C: A Series of Highly Active Inhibitors of Nitric Oxide Production in Mouse Macrophages

AUTHOR(S): Honda, Tadashi; Rounds, BarbieAnn V.; Bore, Lothar; Finlay, Heather J.; Favaloro, Frank G. ,Jr.; Suh, Nanjoo; Wang, Yongping; Sporn, Michael B.; Gribble, Gordon W.

CORPORATE SOURCE: Department of Chemistry, Dartmouth College Dartmouth Medical School, Hanover, NH, 03755, USA

SOURCE: Journal of Medicinal Chemistry (2000), 43(22), 4233-4246
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 133:350364

AB New olean- and urs-1-en-3-one triterpenoids with various modified rings C have been synthesized as potential antiinflammatory and cancer chemopreventive agents and evaluated for their inhibitory activities against production of nitric oxide induced by interferon-γ in mouse macrophages. These studies revealed that 9(11)-en-12-one and 12-en-11-one

functionalities in ring C increase the potency by about 2-10 times compared with the original 12-ene. Subsequently, novel olean- and urs-1-en-3-one derivs. with nitrile and carboxyl groups at C-2 in ring A and with 9(11)-en-12-one and 12-en-11-one functionalities in ring C were synthesized. Among them, Me 2-cyano-3, 12-dioxooleana-1,9(11)-dien-28-oate, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) (I), and Me 2-carboxy-3,12-dioxooleana-1,9(11)-dien-28-oate were found to have extremely high potency (IC50 = 0.1 nM level). Their potency is similar to that of dexamethasone although they do not act through the glucocorticoid receptor. Overall, the combination of modified rings A and C increases the potency by about 10 000 times compared with the lead compound, 3-oxooleana-1,12-dien-28-oic acid (IC50 = 1 μM level). The selected oleanane triterpenoid, I, was found to be a potent, multifunctional agent in various in vitro assays and to show antiinflammatory activity against thioglycollate-interferon-γ-induced mouse peritonitis.

IT 218600-53-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthetic oleanane and ursane triterpenoids, a series of highly active inhibitors of nitric oxide production in mouse macrophages)

RN 218600-53-4 CAPLUS
CN Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 6 USPATFULL on STN
ACCESSION NUMBER: 2001:221178 USPATFULL
TITLE: Therapeutic compounds and methods of use
INVENTOR(S): Gribble, Gordon W., Norwich, VT, United States
Honda, Tadashi, Hanover, NH, United States
Sporn, Michael B., Tunbridge, VT, United States
Suh, Nanjoo, Hanover, NH, United States
PATENT ASSIGNEE(S): Trustees of Dartmouth College, Hanover, NH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6326507	B1	20011204
APPLICATION INFO.:	US 1999-335003		19990617 (9)

NUMBER DATE

PRIORITY INFORMATION:	US 1998-90053P	19980619 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Higel, Floyd D.	
ASSISTANT EXAMINER:	Sackey, Ebenezer	
LEGAL REPRESENTATIVE:	Fulbright & Jaworski, LLP	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 11 Drawing Page(s)	
LINE COUNT:	964	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 218600-53-4
(reaction; triterpenoids for treatment of cancer, neurodegenerative, diseases, and inflammatory bowel diseases)

RN 218600-53-4 USPATFULL

CN Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



=> file uspatfull

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	47.37	227.94

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.00	-4.00

FILE 'USPATFULL' ENTERED AT 16:33:42 ON 24 APR 2008

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Apr 2008 (20080424/PD)
FILE LAST UPDATED: 24 Apr 2008 (20080424/ED)
HIGHEST GRANTED PATENT NUMBER: US7363658
HIGHEST APPLICATION PUBLICATION NUMBER: US2008098499
CA INDEXING IS CURRENT THROUGH 24 Apr 2008 (20080424/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Apr 2008 (20080424/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2008

=> s l3
L7 5 L3

=> d l7 1-5 ibib, abs, hitstr

L7 ANSWER 1 OF 5 USPATFULL on STN

ACCESSION NUMBER:	2005:331377 USPATFULL		
TITLE:	Therapeutic compositions and methods of use		
INVENTOR(S):	Gribble, Gordon W., Norwich, VT, UNITED STATES Honda, Tadashi, Hanover, NH, UNITED STATES Sporn, Michael B., Tunbridge, VT, UNITED STATES Suh, Nanjoo, Hanover, NH, UNITED STATES		
PATENT ASSIGNEE(S):	Trustees of Dartmouth College (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005288363	A1	20051229
APPLICATION INFO.:	US 2005-121316	A1	20050503 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-395372, filed on 24 Mar 2003, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FULBRIGHT & JAWORSKI L.L.P., 600 CONGRESS AVE., SUITE 2400, AUSTIN, TX, 78701, US		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	11 Drawing Page(s)		
LINE COUNT:	931		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 218600-53-4
(reaction; triterpenoids for treatment of cancer, neurodegenerative, diseases, and inflammatory bowel diseases)

RN 218600-53-4 USPATFULL

CN Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 2 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2003:335425 USPATFULL

TITLE: Therapeutic compositions and methods of use

INVENTOR(S): Gribble, Gordon W., Norwich, VT, UNITED STATES
Honda, Tadashi, Hanover, NH, UNITED STATES
Sporn, Michael B., Tunbridge, VT, UNITED STATES
Suh, Nanjoo, Hanover, NH, UNITED STATES

PATENT ASSIGNEE(S): Trustees of Darmouth College (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003236303	A1	20031225
	US 7288568	B2	20071030
APPLICATION INFO.:	US 2003-395372	A1	20030324 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-927081, filed on 9 Aug 2001, GRANTED, Pat. No. US 6552075 Division of Ser. No. US 1999-335003, filed on 17 Jun 1999, GRANTED, Pat. No. US 6326507

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-90053P	19980619 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: Steven L. Highlander, Esq., FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701

NUMBER OF CLAIMS: 73

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 14 Drawing Page(s)

LINE COUNT: 1146

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 218600-53-4
(reaction; triterpenoids for treatment of cancer, neurodegenerative, diseases, and inflammatory bowel diseases)

RN 218600-53-4 USPATFULL

CN Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER:	2003:173884 USPATFULL		
TITLE:	CDDO-compounds and combination therapies thereof		
INVENTOR(S):	Konopleva, Marina, Houston, TX, UNITED STATES Andreeff, Michael, Houston, TX, UNITED STATES Sporn, Michael B., Tunbridge, VT, UNITED STATES		
PATENT ASSIGNEE(S):	Board of (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003119732	A1	20030626
APPLICATION INFO.:	US 2001-998009	A1	20011128 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-253673P		20001128 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Priya D. Subramony, Fulbright & Jaworski L.L.P., 600 Congress Avenue, Suite 2400, Austin, TX, 78701		
NUMBER OF CLAIMS:	79		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	35 Drawing Page(s)		
LINE COUNT:	5276		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB CDDO-compounds in combination with other chemotherapeutic agents induce and potentiate cytotoxicity and apoptosis in cancer cell. One class of chemotherapeutic agents include retinoids. Cancer therapies based on these combination therapies are provided. Also provided are methods to treat graft versus host diseases using the CDDO compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 218600-53-4
(CDDO compds. and combinations with other chemotherapeutics for treatment of cancer and graft vs. host disease)

RN 218600-53-4 USPATFULL

CN Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER:	2002:78876 USPATFULL
TITLE:	Therapeutic compounds and methods of use
INVENTOR(S):	Gribble, Gordon W., Norwich, VT, UNITED STATES Honda, Tadashi, Hanover, NH, UNITED STATES Sporn, Michael B., Tunbridge, VT, UNITED STATES Suh, Nanjoo, Hanover, NH, UNITED STATES
PATENT ASSIGNEE(S):	Trustees of Dartmouth College (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002042535	A1	20020411
	US 6552075	B2	20030422
APPLICATION INFO.:	US 2001-927081	A1	20010809 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1999-335003, filed on 17 Jun 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-90053P	19980619 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Steven L. Highlander, FULBRIGHT & JAWORSKI L.L.P., Suite 2400, 600 Congress Avenue, Austin, TX, 78701
NUMBER OF CLAIMS:	73
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	11 Drawing Page(s)
LINE COUNT:	1150

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 218600-53-4
(reaction; triterpenoids for treatment of cancer, neurodegenerative, diseases, and inflammatory bowel diseases)

RN 218600-53-4 USPATFULL

CN Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 5 OF 5 USPATFULL on STN

ACCESSION NUMBER:	2001:221178 USPATFULL
TITLE:	Therapeutic compounds and methods of use
INVENTOR(S):	Gribble, Gordon W., Norwich, VT, United States Honda, Tadashi, Hanover, NH, United States Sporn, Michael B., Tunbridge, VT, United States Suh, Nanjoo, Hanover, NH, United States
PATENT ASSIGNEE(S):	Trustees of Dartmouth College, Hanover, NH, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6326507	B1	20011204
APPLICATION INFO.:	US 1999-335003		19990617 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-90053P	19980619 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Higel, Floyd D.
ASSISTANT EXAMINER:	Sackey, Ebenezer
LEGAL REPRESENTATIVE:	Fulbright & Jaworski, LLP
NUMBER OF CLAIMS:	13
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	14 Drawing Figure(s); 11 Drawing Page(s)
LINE COUNT:	964

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds and methods useful for chemopreventative treatment of diseases such as cancer, Alzheimer's disease, Parkinson's disease, inflammatory bowel diseases, and multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 218600-53-4
(reaction; triterpenoids for treatment of cancer, neurodegenerative, diseases, and inflammatory bowel diseases)

RN 218600-53-4 USPATFULL

CN Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



=> d his

(FILE 'HOME' ENTERED AT 16:31:27 ON 24 APR 2008)

FILE 'REGISTRY' ENTERED AT 16:31:43 ON 24 APR 2008
L1 STRUCTURE UPLOADED
L2 0 S L1 EXA
L3 2 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 16:32:31 ON 24 APR 2008
L4 34 S L3
L5 28 S L4 AND (CANCER? OR ?TUMOR?)
L6 6 S L5 NOT PY>2002

FILE 'USPATFULL' ENTERED AT 16:33:42 ON 24 APR 2008
L7 5 S L3

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	31.79	259.73

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-4.00

STN INTERNATIONAL LOGOFF AT 16:34:31 ON 24 APR 2008